Testosterone Measurement in Patients with Prostate Cancer

European Urology

Volumn 58, Issue 1, 2010, Pages 65-74

  Schulman, Claude C ^a   Irani, Jacques ^b   Morote, Juan ^c   Schalken, Jack A ^d   Montorsi, Francesco ^e   Chlosta, Piotr L ^f   Heidenreich, Axel ^g  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f Institute of Oncology   (Poland)

^g RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Androgen deprivation therapy; Androgen receptor; Luteinising hormone releasing hormone agonist; Prostate cancer; Testosterone measurement

Indexed keywords

ANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADD ON THERAPY; ANDROGEN DEPRIVATION THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CASTRATION; CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; DRUG TARGETING; HUMAN; INFORMATION RETRIEVAL; MEASUREMENT; MEDICAL DECISION MAKING; MEDLINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 77952875970     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.04.001     Document Type: Review

References (69)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer I. The effect of castration, of estrogen, and of androgen injection on serum phosphatises in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Zlotta A., and Debruyne F.M.J. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl 4 8 (2005) 37-41
3. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Prostate_Cancer.pdf. Updated 2009. Accessed December 2009.
4. Greene K.L., Albertsen P.C., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 182 (2009) 2232-2241
5. Heemers H.V., and Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28 (2007) 778-808
6. Vis A.N., and Schröder F.H. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 104 (2009) 438-448
7. Deslypere J.P., Young M., Wilson J.D., and McPhaul M.J. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 88 (1992) 15-22
8. Schalken J.A. Molecular aspects of hormone-independent prostate cancer. BJU Int 100 Suppl 2 (2007) 52-55
9. Dehm S.M., and Tindall D.J. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 21 (2007) 2855-2863
10. Isaacs J.T., Lundmo P.I., Berges R., Martikainen P., Kyprianou N., and English H.F. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13 (1992) 457-464
11. Ling M.T., Chan K.W., and Choo C.K. Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 170 (2001) 287-296
12. Nelson P.S., Clegg N., Arnold H., et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 99 (2002) 11890-11895
13. Rittmaster R.S., Fleshner N.E., and Thompson I.M. Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol 55 (2009) 1064-1074
14. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
15. Andriole G., Bostwick D., Brawley O., et al. Further analyses from the REDUCE prostate cancer risk reduction trial [abstract]. J Urol 181 Suppl (2009) 555
16. Harris W.P., Mostaghel E.A., Nelson P.S., and Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6 (2009) 76-85
17. Tindall D.J., and Rittmaster R.S. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 179 (2008) 1235-1242
18. Morgentaler A., and Traish A.M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55 (2009) 310-321
19. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
20. Tomlins S.A., Bjartell A., Chinnaiyan A.M., et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56 (2009) 275-286
21. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 (2004) 1488-1490
22. van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48 (1991) 189-193
23. Gregory C.W., Johnson Jr. R.T., Mohler J.L., French F.S., and Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 (2001) 2892-2898
24. Gardiner R.A., Sweeney C., and Tilley W.D. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach. Eur Urol 56 (2009) 245-246
25. Szmulewitz R., Mohile S., Posadas E., et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 56 (2009) 97-104
26. Morris M.J., Huang D., Kelly W.K., et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 56 (2009) 237-244
27. Taplin M.E., Rajeshkumar B., Halabi S., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21 (2003) 2673-2678
28. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315-4319
29. Craft N., Shostak Y., Carey M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280-285
30. Mohler J.L., Gregory C.W., Ford III O.H., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004) 440-448
31. Mostaghel E.A., Page S.T., Lin D.W., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67 (2007) 5033-5041
32. Mostaghel E.A., and Nelson P.S. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22 (2008) 243-258
33. Locke J.A., Guns E.S., Lubik A.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68 (2008) 6407-6415
34. Grossmann M.E., Huang H., and Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93 (2001) 1687-1697
35. Carpenter W.R., Robinson W.R., and Godley P.A. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst 100 (2008) 158-159
36. Roddam A.W., Allen N.E., Appleby P., Key T.J., and Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100 (2008) 170-183
37. Morote J., Ramirez C., Gómez E., et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 104 (2009) 486-489
38. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296 (2006) 2351-2361
39. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
40. Schatzl G., Madersbacher S., Thurridl T., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
41. San Francisco I.F., Regan M.M., DeWolf W.C., and Olumi A.F. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341-1345
42. Massengill J.C., Sun L., Moul J.W., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
43. Teloken C., Da Ros C.T., Caraver F., Weber F.A., Cavalheiro A.P., and Graziottin T.M. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178-2180
44. Pierorazio P.M., Ferrucci L., Kettermann A., Longo D.L., Metter E.J., and Carter H.B. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 105 (2010) 824-829
45. Isbarn H., Pinthus J.H., Marks L.S., et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 56 (2009) 48-56
46. Loeb S., and Catalona W.J. What to do with an abnormal PSA test. Oncologist 13 (2008) 299-305
47. Morote J., Planas J., Ramirez C., et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int 105 (2010) 481-484
48. Karamanolakis D., Lambou T., Bogdanos J., et al. Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (≥3. 0 and <10.0 ng/ml). Anticancer Res 26 (2006) 3159-3166
49. Rhoden E.L., Riedner C.E., and Morgentaler A. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 179 (2008) 1741-1744
50. Yamamoto S., Yonese J., Kawakami S., et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 52 (2007) 696-701
51. Ribeiro M., Ruff P., and Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20 (1997) 605-608
52. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350 (2004) 482-492
53. Freedland S.J., and Platz E.A. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29 (2007) 88-97
54. Taira A.V., Merrick G.S., Galbreath R.W., et al. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys 74 (2009) 1143-1149
55. Pathak A.S., Pacificar J.S., Shapiro C.E., and Williams S.G. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol 177 (2007) 2132-2135
56. Tombal B., and Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 7 (2008) 15-21
57. Morote J., Planas J., Salvador C., Raventós C.X., Catalán R., and Reventós J. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 103 (2009) 332-335
58. Morote J., Orsola A., Planas J., et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178 (2007) 1290-1295
59. Koo V., Young M., and O'Brien A. Pitfalls of hormonal injection therapy in prostate cancer. Int J Clin Pract 63 (2009) 820-822
60. Taieb J., Mathian B., Millot F., et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49 (2003) 1381-1395
61. Schulman C.C. Intermittent hormone therapy: what is its place in clinical practice?. Eur Urol Suppl 8 (2009) 852-856
62. Boccon-Gibod L., Hammerer P., Madersbacher S., Mottet N., Prayer-Galetti T., and Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 100 (2007) 738-743
63. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99 Suppl 1 (2007) 19-22
64. Calais da Silva F.E.C., Bono A.V., Whelan P., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 55 (2009) 1269-1277
65. Tunn U., Kurek R., Keinle E., et al. Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy [abstract]. J Urol 171 (2004) 384
66. Gleave M., Klotz L., and Taneja S.S. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 27 (2009) 81-86
67. Shaw G., and Oliver R.T. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surg Oncol 18 (2009) 275-282
68. Oefelein M.G. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 169 (2003) 251-255
69. Blumberg J.M., Kwon E., Cheetham T.C., et al. Treatment failure is associated with different dosing regimens of luteinizing hormone releasing hormone agonist therapy for prostate cancer [abstract]. J Urol 181 Suppl (2009) 96-97